Senior Director - Innovation, CLP Group
Qiming Venture Partners
While COVID-19 has caused many investors to take a pause, for Nisa Leung the pandemic has become an opportunity.
Leung heads up the healthcare portfolio at China-focused Qiming Venture Partners. Qiming has invested in over 100 startups in the sector, primarily in diagnostics, R&D, equipment, and services fields. Leung says her current portfolio includes over 60 companies directly involved in combating COVID-19.
Back in April, Leung was herself feeling the direct impact of COVID-19 after she had to self-quarantine in Hong Kong following a trip to the US, where she had been putting together a new $1.1 billion fund to invest in Chinese startups. This new fund raised Qiming’s total assets under management to $5.3 billion, split across nine US-dollar funds and five RMB funds.
Leung’s portfolio is a who’s who of China’s most successful and innovative healthcare firms. In June, one of Qiming’s earliest investments in the biopharma space — insulin manufacturer Gan & Lee Pharmaceuticals — listed on the Shanghai A-shares board, raising over $360 million.
Leung is also eyeing the growing med-tech sector. Qiming entered recently into a partnership with cardiovascular-device company Venus Medtech and DCP Capital to form Ascendum Capital Partners, a platform to invest in innovative medical device companies, with the aim of accelerating R&D and commercialization.